Merck received FDA approval for Enflonsia (cesrovimab), a long-acting monoclonal antibody preventing RSV lower respiratory tract disease in infants, joining existing pediatric RSV antibody products on the market. This approval extends Merck’s presence in the competitive RSV prevention segment. The timing coincides with restructuring at the CDC’s vaccine advisory committee, which may influence forthcoming immunization recommendations.